{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:47:09Z","timestamp":1778665629092,"version":"3.51.4"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"Supplement_4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,4,15]]},"DOI":"10.1086\/500663","type":"journal-article","created":{"date-parts":[[2006,3,20]],"date-time":"2006-03-20T15:33:22Z","timestamp":1142868802000},"page":"S164-S172","source":"Crossref","is-referenced-by-count":198,"title":["Extended-Spectrum \u03b2-Lactamases and Clinical Outcomes: Current Data"],"prefix":"10.1093","volume":"42","author":[{"given":"Reuben","family":"Ramphal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul G. Ambrose","family":">","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2006,4,15]]},"reference":[{"key":"key\n\t\t\t\t20171014010058_ref1","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1046\/j.1469-0691.2000.00107.x","article-title":"Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum \u03b2-lactamases (ESBLs)","volume":"6","author":"Paterson","year":"2000","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20171014010058_ref2","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1128\/JCM.39.6.2206-2212.2001","article-title":"Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum \u03b2-lactamases: implications for the clinical microbiology laboratory","volume":"39","author":"Paterson","year":"2001","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20171014010058_ref3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1086\/324742","article-title":"Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime","volume":"34","author":"Wong-Beringer","year":"2002","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014010058_ref4","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1592\/phco.21.6.583.34537","article-title":"Therapeutic challenges associated with extended-spectrum, beta- lactamase-producing Escherichia coli and Klebsiella pneumoniae","volume":"21","author":"Wong-Beringer","year":"2001","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t20171014010058_ref5","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1007\/s00134-002-1521-1","article-title":"Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome","volume":"28","author":"Du","year":"2002","journal-title":"Intensive Care Med"},{"key":"key\n\t\t\t\t20171014010058_ref6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/infdis\/174.3.529","article-title":"Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation","volume":"174","author":"Schiappa","year":"1996","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20171014010058_ref7","article-title":"Extended-spectrum \u03b2-lactamase (ESBL) producing Klebsiella pneumoniae bacteremia: risk factors and outcome [abstract 95]","volume-title":"Presented at the 39th Annual Meeting of the Infectious Disease Society of America (San Francisco)","author":"Yoon","year":"2001"},{"key":"key\n\t\t\t\t20171014010058_ref8","article-title":"Clinical and microbiological significance of blood stream infection due to ESBL-producing Klebsiella pneumoniae: a case-control study [abstract 96]","volume-title":"Presented at the 39th Annual Meeting of the Infectious Disease Society of America (San Francisco)","author":"Chemaly","year":"2001"},{"key":"key\n\t\t\t\t20171014010058_ref9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1053\/jhin.2002.1288","article-title":"Clinical implications of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteraemia","volume":"52","author":"Kim","year":"2002","journal-title":"J Hosp Infect"},{"key":"key\n\t\t\t\t20171014010058_ref10","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1128\/JCM.35.8.2061-2067.1997","article-title":"Detection and clinical significance of extended-spectrum \u03b2-lactamases in a tertiary-care medical center","volume":"35","author":"Emery","year":"1997","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20171014010058_ref11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1201-9712(00)90061-4","article-title":"Ceftazidime-resistant Klebsiella pneumoniae bloodstream infection in children with febrile neutropenia","volume":"4","author":"Ariffin","year":"2000","journal-title":"Int J Infect Dis"},{"key":"key\n\t\t\t\t20171014010058_ref12","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1128\/AAC.46.5.1481-1491.2002","article-title":"Bloodstream infections by extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome","volume":"46","author":"Kim","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014010058_ref13","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/00365540210147516","article-title":"Bacteremia caused by Escherichia coli producing extended-spectrum beta-lactamase: a case-control study of risk factors and outcomes","volume":"34","author":"Ho","year":"2002","journal-title":"Scand J Infect Dis"},{"key":"key\n\t\t\t\t20171014010058_ref14","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1128\/AAC.34.11.2193","article-title":"Outbreak of ceftazidime resistance caused by extended-spectrum \u03b2-lactamases at a Massachusetts chronic-care facility","volume":"34","author":"Rice","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014010058_ref15","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1128\/AAC.34.6.1290","article-title":"Failure of ceftazidime-amikacin therapy for bacteremia and meningitis due to Klebsiella pneumoniae producing an extended-spectrum \u03b2-lactamase","volume":"34","author":"Smith","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014010058_ref16","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1128\/AAC.33.9.1451","article-title":"Novel plasmid-mediated \u03b2-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae","volume":"33","author":"Quinn","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014010058_ref17","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1128\/AAC.46.6.1985-1988.2002","article-title":"CTX-M-14, a plasmid-mediated CTX-M type extended-spectrum \u03b2-lactamase isolated from Escherichia coli","volume":"46","author":"Ma","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014010058_ref18","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1128\/AAC.46.6.2000-2003.2002","article-title":"TEM-71, a novel plasmid-encoded, extended-spectrum \u03b2-lactamase produced by a clinical isolate of Klebsiella pneumoniae","volume":"46","author":"Rasheed","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014010058_ref19","article-title":"Performance standards for antimicrobial susceptibility testing","volume-title":"14th Informational supplement. NCCLS document M100-S14","author":"NCCLS","year":"2004"},{"key":"key\n\t\t\t\t20171014010058_ref20","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/jac\/38.3.409","article-title":"Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe","volume":"38","author":"Livermore","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171014010058_ref21","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0140-6736(87)90891-9","article-title":"Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae","volume":"2","author":"Brun-Buisson","year":"1987","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171014010058_ref22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/jac\/37.1.203","article-title":"Treatment failure due to extended spectrum beta-lactamase","volume":"37","author":"Karas","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171014010058_ref23","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/clinids\/23.1.118","article-title":"Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center","volume":"23","author":"Rice","year":"1996","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014010058_ref24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.diagmicrobio.2004.07.006","article-title":"The inoculum effect: fact or artifact?","volume":"50","author":"Craig","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171014010058_ref25","article-title":"Impact of extended-spectrum beta-lactamase production on the activity of cefepime in a murine-thigh infection model [abstract 1099]","volume-title":"Program and abstracts of the 41st Interscience Conference on Antimicrobial Chemotherapy (Chicago)","author":"Andes","year":"2001"},{"key":"key\n\t\t\t\t20171014010058_ref26","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1128\/AAC.48.6.1941-1947.2004","article-title":"Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-\u03b2-lactamase-producing Escherichia coli at various inocula","volume":"48","author":"Maglio","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014010058_ref27","article-title":"Use of pharmacokinetics-pharmacodynamics and Monte Carlo simulation as decision support for the re-evaluation of NCCLS cephem susceptibility breakpoints for Enterobacteriaceae [poster A-138]","volume-title":"Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC)","author":"Ambrose","year":"2004"},{"key":"key\n\t\t\t\t20171014010058_ref28","doi-asserted-by":"crossref","first-page":"353","DOI":"10.7326\/0003-4819-119-5-199309010-00001","article-title":"Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins","volume":"119","author":"Meyer","year":"1993","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20171014010058_ref29","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0732-8893(01)00320-0","article-title":"MYSTIC program: summary of European data from 1997 to 2000","volume":"41","author":"Goossens","year":"2001","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171014010058_ref30","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0732-8893(02)00540-0","article-title":"Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000)","volume":"45","author":"Hoban","year":"2003","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171014010058_ref31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1179\/joc.2002.14.1.25","article-title":"Antimicrobial resistance in gram-negative isolates from European intensive care units: data from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme","volume":"14","author":"Garcia-Rodriguez","year":"2002","journal-title":"J Chemother"},{"key":"key\n\t\t\t\t20171014010058_ref32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0732-8893(01)00319-4","article-title":"Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA)","volume":"41","author":"Pfaller","year":"2001","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171014010058_ref33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0732-8893(00)00234-0","article-title":"Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia. I. Results from the SENTRY Antimicrobial Surveillance Program (North America, 1998)","volume":"39","author":"Mathai","year":"2001","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171014010058_ref34","first-page":"226","article-title":"In vitro antimicrobial activity of piperacillin\/tazobactam in comparison with other broad-spectrum beta-lactams","volume":"4","author":"Roland","year":"2000","journal-title":"Braz J Infect Dis"},{"key":"key\n\t\t\t\t20171014010058_ref35","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1055\/s-2007-993898","article-title":"Piperacillin\/tazobactam in the treatment of Klebsiella pneumoniae infections in neonates","volume":"15","author":"Pillay","year":"1998","journal-title":"Am J Perinatol"},{"key":"key\n\t\t\t\t20171014010058_ref36","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1046\/j.1469-0691.2003.00555.x","article-title":"Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum \u03b2-lactamase in Europe","volume":"9","author":"Jones","year":"2003","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 2","key":"key\n\t\t\t\t20171014010058_ref37","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1086\/320182","article-title":"Variations in the prevalence of strains expressing an extended-spectrum \u03b2-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region","volume":"32","author":"Winokur","year":"2001","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014010058_ref38","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2174\/0929867023370923","article-title":"In vitro and in vivo activities of ciprofloxacin and levofloxacin against an SHV-5 extended-spectrum \u03b2-lactamase-producing Klebsiella pneumoniae strain","volume":"9","author":"Szabo","year":"2002","journal-title":"Curr Med Chem"},{"key":"key\n\t\t\t\t20171014010058_ref39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/jac\/48.1.37","article-title":"Activity of levofloxacin and ciprofloxacin against urinary pathogens","volume":"48","author":"Drago","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171014010058_ref40","first-page":"196","article-title":"Antimicrobial susceptibility of Klebsiella pneumoniae producing extended-spectrum beta-lactamase (ESBL) isolated in hospitals in Brazil","volume":"1","author":"Gales","year":"1997","journal-title":"Braz J Infect Dis"},{"key":"key\n\t\t\t\t20171014010058_ref41","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1086\/313719","article-title":"Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum \u03b2-lactamase production in Klebsiella pneumoniae isolates causing bacteremia","volume":"30","author":"Paterson","year":"2000","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014010058_ref42","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1128\/AAC.46.1.196-202.2002","article-title":"Occurrence of extended-spectrum \u03b2-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to \u03b2-lactams and other antimicrobial drugs","volume":"46","author":"Spanu","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014010058_ref43","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0732-8893(01)00353-4","article-title":"Prevalence of extended spectrum \u03b2-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998\u201399)","volume":"42","author":"Bell","year":"2002","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171014010058_ref44","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.1128\/JCM.40.12.4666-4669.2002","article-title":"Molecular epidemiology of extended-spectrum \u03b2-lactamase-producing, fluoroquinolone-resistant isolates of Klebsiella pneumoniae in Taiwan","volume":"40","author":"Yu","year":"2002","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20171014010058_ref45","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1086\/342577","article-title":"Molecular epidemiology of a citywide outbreak of extended-spectrum \u03b2-lactamase\u2014producing Klebsiella pneumoniae infection","volume":"35","author":"Quale","year":"2002","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014010058_ref46","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1086\/322667","article-title":"Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum \u03b2-lactamase\u2014producing Escherichia coli and Klebsiella pneumoniae","volume":"33","author":"Lautenbach","year":"2001","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014010058_ref47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0924-8579(02)00249-2","article-title":"Sustained activity and spectrum of selected extended-spectrum \u03b2-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997\u20132000)","volume":"21","author":"Jones","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20171014010058_ref48","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/jac\/49.3.445","article-title":"Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime","volume":"49","author":"Ambrose","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171014010058_ref49","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1128\/AAC.47.5.1643-1646.2003","article-title":"Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum \u03b2-lactamases: report from the ARREST Program","volume":"47","author":"Ambrose","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014010058_ref50","article-title":"Cefepime for the treatment of infections due to ESBL-producing Enterobacter aerogenes [abstract K-718]","volume-title":"Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago)","author":"Goethaert","year":"2003"},{"key":"key\n\t\t\t\t20171014010058_ref51","first-page":"42","article-title":"Outcomes of infections caused by extended spectrum beta-lactamase (ESBL) producing strains of E. coli and Klebsiella spp. treated with cefepime [abstract O275]","volume-title":"Programs and abstracts of the 12th European Congress of Clinical Microbiology and Infectious Diseases (Milan)","author":"Ramphal","year":"2002"},{"key":"key\n\t\t\t\t20171014010058_ref52","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1128\/AAC.47.11.3442-3447.2003","article-title":"Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study","volume":"47","author":"Zanetti","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014010058_ref53","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1592\/phco.22.1.81.33508","article-title":"The effect of an antimicrobial formulary change on hospital resistance patterns","volume":"22","author":"Empey","year":"2002","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t20171014010058_ref54","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jama.280.14.1233","article-title":"Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella","volume":"280","author":"Rahal","year":"1998","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20171014010058_ref55","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1086\/502018","article-title":"The cost of antibiotic resistance: effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudmonas aeruginosa on length of hospital stay","volume":"23","year":"2002","journal-title":"Infect Control Hosp Epidemiol"},{"key":"key\n\t\t\t\t20171014010058_ref56","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1086\/319757","article-title":"Extended-spectrum \u03b2-lactamase\u2014producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes","volume":"32","author":"Lautenbach","year":"2001","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/42\/Supplement_4\/S164\/20907220\/42-Supplement_4-S164.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T08:00:35Z","timestamp":1586764835000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/cid\/article\/42\/Supplement_4\/S164\/324664\/ExtendedSpectrum-\u03b2Lactamases-and-Clinical-Outcomes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,15]]},"references-count":56,"journal-issue":{"issue":"Supplement_4","published-online":{"date-parts":[[2006,4,15]]},"published-print":{"date-parts":[[2006,4,15]]}},"URL":"https:\/\/doi.org\/10.1086\/500663","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,4,15]]},"published":{"date-parts":[[2006,4,15]]}}}